Bleecker ER, et al. - Researchers analyzed pooled data from the SIROCCO and CALIMA Phase III studies to determine how baseline factors (including oral corticosteroid [OCS] use, nasal polyposis, prebronchodilator forced vital capacity [FVC], prior year exacerbations, and age at diagnosis) influence benralizumab's efficacy in patients with severe asthma. Participants were patients aged 12–75 years with severe, uncontrolled asthma receiving high-dosage inhaled corticosteroids plus long-acting β2-agonists. These patients were treated with benralizumab 30 mg subcutaneously every 8 weeks (Q8W, first three doses every 4 weeks [Q4W]), Q4W, or placebo. According to findings, patients potentially responsive to benralizumab could be detected with the help of baseline clinical factors and blood eosinophil counts. Also, data showed that OCS use, nasal polyposis, and FVC <65% of predicted were related to greater benralizumab Q8W responsiveness for reduced exacerbation rate for patients with <300 eosinophils·μL⁻¹.